\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ significant\\ for\\ mild\\,\\ non\\-tender\\ cervical\\ lymphadenopathy\ \(0\)\
\-\ laboratory\\ unremarkable\ \(0\)\
\-\ patient\\ was\\ recently\\ diagnosed\\ and\\ is\\ undergoing\\ radiation\\ therapy\\ at\\ this\\ time\\.\ \(0\)\
\-\ \\‚\\Ä\\¢\\ cxr\\:\\ enlargement\\ of\\ the\\ right\\ paratracheal\\ stripe\\ \\(8mm\\)\\.\ \(0\)\
\-\ \\‚\\Ä\\¢\\ ct\\,\\ neck\\:\\ \\ 2\\.4\\ x\\ 2\\.4\\ cm\\ mediastinal\\ mass\\ \\(enlarged\\ lymph\\ node\\)\ \(0\)\
\-\ classic\\ nodular\\ sclerosing\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ \\(stage\\ ii\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ malignancy\ \(1\)\
\-\ \\¬\\ª\\ hodgkin\\‚\\Ä\\ôs\\ disease\ \(0\)\
\-\ \\¬\\ª\\ non\\-hodgkin\\‚\\Ä\\ôs\\ lymphoma\ \(0\)\
\-\ \\¬\\ª\\ mediastinal\\ malignancy\ \(0\)\
\-\ \\‚\\Ä\\¢\\ benign\\ neoplasm\ \(1\)\
\-\ \\‚\\Ä\\¢\\ granulomatous\\ disease\ \(0\)\
\-\ \\‚\\Ä\\¢\\ other\\ inflammation\\ \\(abscess\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ congenital\\ abnormality\ \(0\)\
\-\ 27\\ yr\\ old\\ woman\\ with\\ c\\/o\\ lymphadenopathy\\ and\\ fatigue\\ for\\ several\\ months\ \(1\)\
\-\ the\\ right\\ paratracheal\\ stripe\\ is\\ usually\\ 2mm\\ wide\\,\\ but\\ may\\ be\\ up\\ to\\ 5mm\\ wide\\.\\ \\ an\\ enlarged\\ paratracheal\\ stripe\\ \\(\\>5mm\\)\\ is\\ an\\ important\\ marker\\ for\\ otherwise\\ subtle\\ adenopathy\\,\\ as\\ well\\ as\\ tracheal\\ tumor\\,\\ mediastinal\\ inflammation\\ or\\ hemorrhage\\,\\ pleural\\ thickening\\ or\\ pleural\\ effusion\\.\\ \\ the\\ margins\\ of\\ the\\ paratracheal\\ stripe\\ are\\:\\ \ \(0\)\
\-\ 1\\.\\ distal\\ end\\‚\\Ä\\îformed\\ by\\ the\\ azygous\\ vein\ \(1\)\
\-\ 2\\.\\ medial\\ margin\\‚\\Ä\\îthe\\ air\\-soft\\ tissue\\ interface\\ along\\ the\\ right\\ mucosal\\ surface\\ of\\ the\\ trachea\ \(1\)\
\-\ 3\\.\\ outer\\ margin\\‚\\Ä\\îbegins\\ around\\ the\\ medial\\ end\\ of\\ the\\ clavicle\\ and\\ is\\ formed\\ by\\ the\\ rul\\ plural\\ surface\ \(0\)\
\-\ the\\ stripe\\ ends\\ where\\ the\\ rul\\ bronchus\\ goes\\ under\\ the\\ azygous\\ vein\\ as\\ it\\ arches\\ anteriorly\\ to\\ empty\\ into\\ the\\ svc\\.\ \(0\)\
\-\ the\\ malignant\\ lymphomas\\ are\\ divided\\ into\\ hodgkin\\‚\\Ä\\ôs\\ and\\ non\\-hodgkin\\‚\\Ä\\ôs\\ groups\\.\\ \\ sir\\ thomas\\ hodgkin\\ was\\ the\\ first\\ to\\ describe\\ hodgkin\\‚\\Ä\\ôs\\ disease\\ in\\ 1932\\.\\ \\ hodgkin\\‚\\Ä\\ôs\\ can\\ present\\ at\\ any\\ age\\,\\ but\\ it\\ is\\ more\\ prevalent\\ among\\ adolescents\\ and\\ young\\ adults\\.\\ \\ it\\ typically\\ presents\\ as\\ painless\\,\\ rubbery\\ lymphadenopathy\\ involving\\ the\\ superficial\\ lymph\\ node\\ groups\\.\\ \\ cervical\\ nodes\\ are\\ involved\\ nearly\\ 70\\%\\ of\\ the\\ time\\.\\ \\ approximately\\ half\\ of\\ patients\\ also\\ have\\ splenomegaly\\.\\ \\ mediastinal\\ involvement\\ occurs\\ in\\ approximately\\ 10\\%\\ of\\ patients\\,\\ and\\ mediastinal\\ involvement\\ is\\ characteristic\\ of\\ the\\ nodular\\ sclerosing\\ type\\ \\(as\\ in\\ this\\ patient\\)\\.\\ \\ cutaneous\\ involvement\\ can\\ occur\\ and\\ is\\ usually\\ a\\ late\\ complication\\.\\ \\ patients\\ may\\ also\\ present\\ with\\ constitutional\\ symptoms\\ \\(night\\ sweats\\,\\ pruritis\\,\\ fatigue\\,\\ weight\\ loss\\,\\ etc\\)\\ with\\ widespread\\ disease\\.\\ \\ \ \(0\)\
\-\ the\\ diagnosis\\ of\\ hodgkin\\‚\\Ä\\ôs\\ disease\\ is\\ made\\ by\\ lymph\\ node\\ biopsy\\ \\(as\\ was\\ done\\ in\\ this\\ patient\\)\\.\\ \\ there\\ are\\ 4\\ histological\\ types\\:\ \(0\)\
\-\ 1\\.\\	nodular\\ sclerosing\\ \\(\\>50\\%\\,\\ most\\ common\\;\\ worst\\ prognosis\\)\ \(0\)\
\-\ 2\\.\\	mixed\\ cellularity\\ \\(25\\%\\)\ \(0\)\
\-\ 3\\.\\	lymphocyte\\ predominant\\ \\(5\\%\\;\\ best\\ prognosis\\)\ \(0\)\
\-\ 4\\.\\	lymphocyte\\ depleted\\ \\(5\\%\\)\ \(0\)\
\-\ staging\\ of\\ hodgkin\\‚\\Ä\\ôs\\ disease\\ is\\ made\\ by\\ the\\ use\\ of\\ cxr\\,\\ bm\\ biopsy\\,\\ and\\ ct\\ imaging\\.\\ \\ there\\ are\\ 4\\ stages\\:\ \(0\)\
\-\ 1\\.\\	stage\\ i\\‚\\Ä\\îconfined\\ to\\ one\\ lymph\\ node\\ group\\ \\(90\\%\\ 5\\-yr\\ survival\\ rate\\)\ \(0\)\
\-\ 2\\.\\	stage\\ ii\\‚\\Ä\\îconfined\\ to\\ 2\\ or\\ more\\ lymph\\ node\\ groups\\ on\\ one\\ side\\ of\\ the\\ diaphragm\ \(0\)\
\-\ 3\\.\\	stage\\ iii\\‚\\Ä\\îinvolving\\ nodes\\ on\\ both\\ sides\\ of\\ the\\ diaphragm\ \(0\)\
\-\ 4\\.\\	stage\\ iv\\‚\\Ä\\îextra\\-nodal\\ disease\\ \\(60\\%\\ 5\\-yr\\ survival\\ rate\\)\\ \ \(0\)\
\-\ treatment\\ involves\\ radiation\\ therapy\\ and\\/or\\ chemotherapy\\.\\ \\ patients\\ with\\ stage\\ i\\ or\\ stage\\ ii\\ hodgkin\\‚\\Ä\\ôs\\ disease\\ are\\ usually\\ treated\\ by\\ radiation\\ therapy\\,\\ while\\ stage\\ iii\\ \\&\\ iv\\ disease\\ is\\ usually\\ treated\\ with\\ radiation\\ therapy\\ and\\ chemotherapy\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\ mendenhall\\,\\ np\\.\\ \\‚\\Ä\\úthe\\ role\\ of\\ radiation\\ in\\ the\\ management\\ of\\ hodgkin\\‚\\Ä\\ôs\\ disease\\:\\ an\\ update\\,\\‚\\Ä\\ù\\ cancer\\ invest\\ 1999\\;\\ 17\\:47\\-55\\.\ \(0\)\
\-\ 2\\.\\ potter\\,\\ r\\.\\ \\‚\\Ä\\úpediatric\\ hodgkin\\‚\\Ä\\ôs\\ disease\\,\\‚\\Ä\\ù\\ eur\\ j\\ cancer\\ 1999\\;\\ 35\\:\\ 1466\\-1477\\.\ \(0\)\
\-\ 3\\.\\ wirth\\,\\ a\\,\\ et\\ al\\,\\ \\‚\\Ä\\úcurrent\\ trends\\ in\\ the\\ management\\ of\\ early\\ stage\\ hodgkin\\‚\\Ä\\ôs\\ disease\\,\\‚\\Ä\\ù\\ aust\\ nz\\ j\\ med\\ 1999\\;\\ 29\\:\\ 535\\-544\ \(0\)\
\-\ 4\\.\\ http\\:\\/\\/www\\.surgical\\-tutor\\-org\\/tutorials\\/hodgkins\\.htm\ \(1\)\
\-\ 5\\.\\ http\\:\\/\\/rad\\.usuhs\\.mil\\/rad\\/chest\\_review\\/mediasti\\/mediasti\\.html\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.48750658425265797\ \(0\)\
\-\ stage\\:\\ 0\\.2443343418049946\ \(0\)\
\-\ stripe\\:\\ 0\\.19594944334832515\ \(0\)\
\-\ the\\:\\ 0\\.1836639124420418\ \(0\)\
\-\ disease\\:\\ 0\\.17172171674341433\ \(0\)\
\-\ paratracheal\\:\\ 0\\.15106030873382584\ \(0\)\
\-\ node\\:\\ 0\\.14650890774805217\ \(0\)\
\-\ mediastinal\\:\\ 0\\.13763917109061224\ \(0\)\
\-\ lymph\\:\\ 0\\.1325470442118692\ \(0\)\
\-\ yr\\:\\ 0\\.11624099560921458\ \(0\)\
\-\ groups\\:\\ 0\\.11561184875001093\ \(0\)\
\-\ radiation\\:\\ 0\\.11295726785809698\ \(0\)\
\-\ sclerosing\\:\\ 0\\.107734511689778\ \(0\)\
\-\ of\\:\\ 0\\.10674296949382518\ \(0\)\
\-\ 1999\\:\\ 0\\.10287803642615781\ \(0\)\
\-\ is\\:\\ 0\\.09336020880012291\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.0876213788211469\ \(0\)\
\-\ usually\\:\\ 0\\.08584590454647799\ \(0\)\
\-\ rul\\:\\ 0\\.08345822082999654\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.08268174315071998\ \(0\)\
\-\ as\\:\\ 0\\.08217311401797918\ \(0\)\
\-\ nodular\\:\\ 0\\.08144478060166488\ \(0\)\
\-\ ii\\:\\ 0\\.08063582327844983\ \(0\)\
\-\ azygous\\:\\ 0\\.07984518941825851\ \(0\)\
\-\ therapy\\:\\ 0\\.07834970128745344\ \(0\)\
\-\ are\\:\\ 0\\.07761564588026523\ \(0\)\
\-\ patients\\:\\ 0\\.07671195232929132\ \(0\)\
\-\ formed\\:\\ 0\\.07416265734312859\ \(0\)\
\-\ involvement\\:\\ 0\\.07402267238920908\ \(0\)\
\-\ 5mm\\:\\ 0\\.0726476494925554\ \(0\)\
\-\ by\\:\\ 0\\.07238483793922797\ \(0\)\
\-\ and\\:\\ 0\\.070444643207215\ \(0\)\
\-\ survival\\:\\ 0\\.06654197362510247\ \(0\)\
\-\ fatigue\\:\\ 0\\.06604039385733944\ \(0\)\
\-\ wide\\:\\ 0\\.06604039385733944\ \(0\)\
\-\ diaphragm\\:\\ 0\\.06604039385733944\ \(0\)\
\-\ end\\:\\ 0\\.060000391582674686\ \(0\)\
\-\ prognosis\\:\\ 0\\.060000391582674686\ \(0\)\
\-\ or\\:\\ 0\\.05929806187915494\ \(0\)\
\-\ iii\\:\\ 0\\.058870174089398396\ \(0\)\
\-\ nodes\\:\\ 0\\.05792037351011691\ \(0\)\
\-\ surface\\:\\ 0\\.056887283469004915\ \(0\)\
\-\ inflammation\\:\\ 0\\.05479722455524544\ \(0\)\
\-\ cxr\\:\\ 0\\.05454425079879649\ \(0\)\
\-\ mendenhall\\:\\ 0\\.05451874911095917\ \(0\)\
\-\ wirth\\:\\ 0\\.05451874911095917\ \(0\)\
\-\ trends\\:\\ 0\\.05451874911095917\ \(0\)\
\-\ aust\\:\\ 0\\.05451874911095917\ \(0\)\
\-\ nz\\:\\ 0\\.05451874911095917\ \(0\)\
\-\ made\\:\\ 0\\.05258609843521953\ \(0\)\
\-\ it\\:\\ 0\\.05235194493771458\ \(0\)\
\-\ invest\\:\\ 0\\.05209557532083201\ \(0\)\
\-\ rate\\:\\ 0\\.05166621667961251\ \(0\)\
\-\ pleural\\:\\ 0\\.051326770148020916\ \(0\)\
\-\ malignancy\\:\\ 0\\.05104329685010843\ \(0\)\
\-\ in\\:\\ 0\\.050884237020512924\ \(0\)\
\-\ http\\:\\ 0\\.0504068883924139\ \(0\)\
\-\ sir\\:\\ 0\\.050376306155829886\ \(0\)\
\-\ rubbery\\:\\ 0\\.050376306155829886\ \(0\)\
\-\ np\\:\\ 0\\.050376306155829886\ \(0\)\
\-\ management\\:\\ 0\\.05036270141485448\ \(0\)\
\-\ depleted\\:\\ 0\\.049042737387105545\ \(0\)\
\-\ potter\\:\\ 0\\.049042737387105545\ \(0\)\
\-\ vein\\:\\ 0\\.048871870958549626\ \(0\)\
\-\ cervical\\:\\ 0\\.048833000798058614\ \(0\)\
\-\ iv\\:\\ 0\\.04871714305264096\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.048413569558589525\ \(0\)\
\-\ arches\\:\\ 0\\.047953132365702734\ \(0\)\
\-\ update\\:\\ 0\\.047953132365702734\ \(0\)\
\-\ biopsy\\:\\ 0\\.04779299176177972\ \(0\)\
\-\ involving\\:\\ 0\\.04775747148655367\ \(0\)\
\-\ thomas\\:\\ 0\\.047031884446663424\ \(0\)\
\-\ enlarged\\:\\ 0\\.0464804225677666\ \(0\)\
\-\ plural\\:\\ 0\\.04623386320070061\ \(0\)\
\-\ goes\\:\\ 0\\.04623386320070061\ \(0\)\
\-\ cancer\\:\\ 0\\.04541388174741467\ \(0\)\
\-\ bm\\:\\ 0\\.04490029443197627\ \(0\)\
\-\ medial\\:\\ 0\\.04438116308270493\ \(0\)\
\-\ lymphomas\\:\\ 0\\.044330693928712896\ \(0\)\
\-\ pruritis\\:\\ 0\\.044330693928712896\ \(0\)\
\-\ cellularity\\:\\ 0\\.044330693928712896\ \(0\)\
\-\ eur\\:\\ 0\\.044330693928712896\ \(0\)\
\-\ prevalent\\:\\ 0\\.04381068941057345\ \(0\)\
\-\ approximately\\:\\ 0\\.043504936460540294\ \(0\)\
\-\ to\\:\\ 0\\.04261327329332205\ \(0\)\
\-\ treated\\:\\ 0\\.04245871668688234\ \(0\)\
\-\ 8mm\\:\\ 0\\.04172911041499827\ \(0\)\
\-\ ends\\:\\ 0\\.04172911041499827\ \(0\)\
\-\ adolescents\\:\\ 0\\.04075785147684699\ \(0\)\
\-\ lymphoma\\:\\ 0\\.040606467634213536\ \(0\)\
\-\ time\\:\\ 0\\.04041305623252301\ \(0\)\
\-\ 2mm\\:\\ 0\\.04018825097358362\ \(0\)\
\-\ widespread\\:\\ 0\\.039922594709129254\ \(0\)\
\-\ splenomegaly\\:\\ 0\\.03966824645544417\ \(0\)\
\-\ an\\:\\ 0\\.03910872168354802\ \(0\)\
\-\ one\\:\\ 0\\.03903726565616719\ \(0\)\
\-\ empty\\:\\ 0\\.03896434183031913\ \(0\)\
\-\ constitutional\\:\\ 0\\.03896434183031913\ \(0\)\
\-\ worst\\:\\ 0\\.03896434183031913\ \(0\)\
\-\ marker\\:\\ 0\\.03874699853640486\ \(0\)\
\-\ describe\\:\\ 0\\.03874699853640486\ \(0\)\
\-\ predominant\\:\\ 0\\.038334677686719824\ \(0\)\
\-\ svc\\:\\ 0\\.03813871646179887\ \(0\)\
\-\ divided\\:\\ 0\\.037948977290442054\ \(0\)\
\-\ histological\\:\\ 0\\.037586667459868994\ \(0\)\
\-\ sides\\:\\ 0\\.037586667459868994\ \(0\)\
\-\ more\\:\\ 0\\.03743908591545322\ \(0\)\
\-\ interface\\:\\ 0\\.037245072665317014\ \(0\)\
\-\ tracheal\\:\\ 0\\.03692195170899495\ \(0\)\
\-\ clavicle\\:\\ 0\\.036766714879537865\ \(0\)\
\-\ stages\\:\\ 0\\.03646783850781952\ \(0\)\
\-\ into\\:\\ 0\\.03624425678008085\ \(0\)\
\-\ bronchus\\:\\ 0\\.03604580801845434\ \(0\)\
\-\ among\\:\\ 0\\.03604580801845434\ \(0\)\
\-\ role\\:\\ 0\\.03578015175399998\ \(0\)\
\-\ can\\:\\ 0\\.03577963444819935\ \(0\)\
\-\ was\\:\\ 0\\.03564303437592426\ \(0\)\
\-\ cutaneous\\:\\ 0\\.03540257682723839\ \(0\)\
\-\ this\\:\\ 0\\.03514272757742559\ \(0\)\
\-\ present\\:\\ 0\\.03498628220077394\ \(0\)\
\-\ sweats\\:\\ 0\\.034821898875189855\ \(0\)\
\-\ staging\\:\\ 0\\.034821898875189855\ \(0\)\
\-\ may\\:\\ 0\\.034311218080247397\ \(0\)\
\-\ med\\:\\ 0\\.034292678808719265\ \(0\)\
\-\ nearly\\:\\ 0\\.03399627350666959\ \(0\)\
\-\ right\\:\\ 0\\.0339076182348144\ \(0\)\
\-\ but\\:\\ 0\\.033715993285739806\ \(0\)\
\-\ etc\\:\\ 0\\.03353276363389077\ \(0\)\
\-\ with\\:\\ 0\\.03337710887270697\ \(0\)\
\-\ patient\\:\\ 0\\.03326416192547671\ \(0\)\
\-\ trachea\\:\\ 0\\.03302019692866972\ \(0\)\
\-\ superficial\\:\\ 0\\.03293888571643501\ \(0\)\
\-\ outer\\:\\ 0\\.03277950875386568\ \(0\)\
\-\ group\\:\\ 0\\.032398725085062696\ \(0\)\
\-\ late\\:\\ 0\\.03218138179114842\ \(0\)\
\-\ mucosal\\:\\ 0\\.03211065573601537\ \(0\)\
\-\ half\\:\\ 0\\.03211065573601537\ \(0\)\
\-\ also\\:\\ 0\\.032070751970929824\ \(0\)\
\-\ adults\\:\\ 0\\.03183583573568653\ \(0\)\
\-\ types\\:\\ 0\\.03170302400536927\ \(0\)\
\-\ painless\\:\\ 0\\.03157309971654243\ \(0\)\
\-\ for\\:\\ 0\\.030998058178762073\ \(0\)\
\-\ undergoing\\:\\ 0\\.030962745062790113\ \(0\)\
\-\ complication\\:\\ 0\\.030962745062790113\ \(0\)\
\-\ anteriorly\\:\\ 0\\.030905002759406466\ \(0\)\
\-\ night\\:\\ 0\\.03062437459089985\ \(0\)\
\-\ pediatric\\:\\ 0\\.03051571192630785\ \(0\)\
\-\ granulomatous\\:\\ 0\\.03030414003014635\ \(0\)\
\-\ current\\:\\ 0\\.02985383055154031\ \(0\)\
\-\ recently\\:\\ 0\\.029758208001021264\ \(0\)\
\-\ 29\\:\\ 0\\.02971096441974921\ \(0\)\
\-\ involves\\:\\ 0\\.029664091380183496\ \(0\)\
\-\ subtle\\:\\ 0\\.0293903206787615\ \(0\)\
\-\ margins\\:\\ 0\\.02908600786356035\ \(0\)\
\-\ important\\:\\ 0\\.02887775397354044\ \(0\)\
\-\ adenopathy\\:\\ 0\\.02867651334729689\ \(0\)\
\-\ under\\:\\ 0\\.02821950489443373\ \(0\)\
\-\ mixed\\:\\ 0\\.02821950489443373\ \(0\)\
\-\ pe\\:\\ 0\\.02818295259756096\ \(0\)\
\-\ 70\\:\\ 0\\.028146622504473556\ \(0\)\
\-\ young\\:\\ 0\\.02811051192990473\ \(0\)\
\-\ 27\\:\\ 0\\.027626617986334104\ \(0\)\
\-\ characteristic\\:\\ 0\\.027560581050239993\ \(0\)\
\-\ best\\:\\ 0\\.02743065676141315\ \(0\)\
\-\ involved\\:\\ 0\\.027335034210894102\ \(0\)\
\-\ 35\\:\\ 0\\.027335034210894102\ \(0\)\
\-\ 90\\:\\ 0\\.02724091759005633\ \(0\)\
\-\ around\\:\\ 0\\.027209871899935564\ \(0\)\
\-\ references\\:\\ 0\\.027178986653373843\ \(0\)\
\-\ there\\:\\ 0\\.0271293158715295\ \(0\)\
\-\ done\\:\\ 0\\.02711769091697983\ \(0\)\
\-\ al\\:\\ 0\\.02708727720295108\ \(0\)\
\-\ occurs\\:\\ 0\\.026878607759483274\ \(0\)\
\-\ where\\:\\ 0\\.026791361218616378\ \(0\)\
\-\ et\\:\\ 0\\.0267053700672948\ \(0\)\
\-\ enlargement\\:\\ 0\\.026135769564031425\ \(0\)\
\-\ use\\:\\ 0\\.026084249573340035\ \(0\)\
\-\ ct\\:\\ 0\\.025957441121539183\ \(0\)\
\-\ at\\:\\ 0\\.02575311881589566\ \(0\)\
\-\ classic\\:\\ 0\\.025498349050870256\ \(0\)\
\-\ 60\\:\\ 0\\.025498349050870256\ \(0\)\
\-\ effusion\\:\\ 0\\.02531515365255932\ \(0\)\
\-\ occur\\:\\ 0\\.025072092053614253\ \(0\)\
\-\ abnormality\\:\\ 0\\.02479702876390809\ \(0\)\
\-\ laboratory\\:\\ 0\\.02475581286324668\ \(0\)\
\-\ diagnosed\\:\\ 0\\.02469451712685267\ \(0\)\
\-\ early\\:\\ 0\\.02457378005260764\ \(0\)\
\-\ congenital\\:\\ 0\\.024494622843607112\ \(0\)\
\-\ otherwise\\:\\ 0\\.024301198779373177\ \(0\)\
\-\ malignant\\:\\ 0\\.024301198779373177\ \(0\)\
\-\ 25\\:\\ 0\\.024150844134574943\ \(0\)\
\-\ typically\\:\\ 0\\.02393217528184221\ \(0\)\
\-\ 50\\:\\ 0\\.023808218324423314\ \(0\)\
\-\ weight\\:\\ 0\\.02377326920781336\ \(0\)\
\-\ side\\:\\ 0\\.023550949825427978\ \(0\)\
\-\ benign\\:\\ 0\\.023418138095110716\ \(0\)\
\-\ neoplasm\\:\\ 0\\.023272170086826874\ \(0\)\
\-\ thickening\\:\\ 0\\.02319259125576482\ \(0\)\
\-\ first\\:\\ 0\\.023005817245425685\ \(0\)\
\-\ type\\:\\ 0\\.02286947029944276\ \(0\)\
\-\ unremarkable\\:\\ 0\\.022854510887605525\ \(0\)\
\-\ along\\:\\ 0\\.02283958882764694\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.022824703933505056\ \(0\)\
\-\ several\\:\\ 0\\.022366965887244558\ \(0\)\
\-\ any\\:\\ 0\\.022032260179228956\ \(0\)\
\-\ while\\:\\ 0\\.022032260179228956\ \(0\)\
\-\ abscess\\:\\ 0\\.021890726974704604\ \(0\)\
\-\ age\\:\\ 0\\.021402596035629648\ \(0\)\
\-\ neck\\:\\ 0\\.02085433941901229\ \(0\)\
\-\ loss\\:\\ 0\\.020769417465637662\ \(0\)\
\-\ on\\:\\ 0\\.020592065763557734\ \(0\)\
\-\ 10\\:\\ 0\\.01993461898417517\ \(0\)\
\-\ months\\:\\ 0\\.01984365403304123\ \(0\)\
\-\ distal\\:\\ 0\\.019807652225922134\ \(0\)\
\-\ significant\\:\\ 0\\.01968332687062753\ \(0\)\
\-\ cm\\:\\ 0\\.019578782830250857\ \(0\)\
\-\ common\\:\\ 0\\.019333437443365083\ \(0\)\
\-\ mild\\:\\ 0\\.01932515430703073\ \(0\)\
\-\ both\\:\\ 0\\.01901075275976713\ \(0\)\
\-\ symptoms\\:\\ 0\\.01865260195021456\ \(0\)\
\-\ imaging\\:\\ 0\\.017915914566481297\ \(0\)\
\-\ tissue\\:\\ 0\\.017883310656327377\ \(0\)\
\-\ tumor\\:\\ 0\\.017831511572277234\ \(0\)\
\-\ woman\\:\\ 0\\.017754645150467034\ \(0\)\
\-\ most\\:\\ 0\\.01774192965224777\ \(0\)\
\-\ other\\:\\ 0\\.017703944681732458\ \(0\)\
\-\ diagnosis\\:\\ 0\\.017672473930185402\ \(0\)\
\-\ have\\:\\ 0\\.01703026774230076\ \(0\)\
\-\ up\\:\\ 0\\.016863476956787665\ \(0\)\
\-\ well\\:\\ 0\\.016506975294392393\ \(0\)\
\-\ presents\\:\\ 0\\.01639947610470537\ \(0\)\
\-\ treatment\\:\\ 0\\.01623929815722516\ \(0\)\
\-\ be\\:\\ 0\\.01382930977103129\ \(0\)\
\-\ mass\\:\\ 0\\.01302180857660692\ \(0\)\
\-\ old\\:\\ 0\\.010089531214758083\ \(0\)\
